Hiroaki Tanaka is an accomplished Strategic Partner with a solid background in technology innovation and a balanced business acumen. With over two decades of relevant experience acquired through various leadership positions in renowned organizations, he has made a significant impact on the life sciences industry.

Tanaka's academic achievements are equally impressive. He has a PhD in fundamental pharmacology from the Paris-Sud University (Paris XI) and an Engineer's degree from École Polytechnique. He also has an Executive MBA from INSEAD.

At present, Tanaka is a Partner at Innogest Capital, where he brings his wealth of knowledge to support and guide emerging firms within the life sciences space framework. Before joining Innogest Capital, he had multiple roles at Debiopharm International SA, Merck Serono, and Serono International, where he led strategic and innovative initiatives.

Tanaka has also been a Board Observer at TcLand Expression and a Supervisory Board Member at Agendia Inc. Moreover, he was the Director of Personalized Medicine and a Member of Investment Committee, Debiopharm Innovation Funds, at Debiopharm International SA. Before that, he held the position of Vice President of Bioinformatics & CIO and Director of bioinformatics at Genset S.A.

In summary, Tanaka's combination of forward-thinking strategy, deep knowledge of cutting-edge technology, and years of expertise in the life sciences sector make him an invaluable asset to organizations.